liu.seSearch for publications in DiVA
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The mu-Opioid Receptor and Treatment Response to Naltrexone
Linköping University, Department of Clinical and Experimental Medicine, Division of Cell Biology. Linköping University, Faculty of Health Sciences. (LBIN)
2013 (English)In: Alcohol and Alcoholism, ISSN 0735-0414, E-ISSN 1464-3502, Vol. 48, no 4, 402-408 p.Article, review/survey (Refereed) Published
Abstract [en]

AIMS:

To evaluate the pharmacogenetic evidence relating to the use of opioid antagonists (in particular naltrexone) in treating patients with alcohol abuse problems.

METHODS:

Narrative review of pre-clinical and clinical published research regarding genetic modulation of psychotropic effects produced by alcohol and the therapeutic effects of opioid antagonists.

RESULTS:

Alcohol activates brain reward pathways, leading to positive reinforcement of alcohol seeking and consumption. Thus, the underlying biological mechanisms may be targets for treatment, particularly in the early stages of addiction development. Alcohol reward is in part mediated by endogenous opioids. A single-nucleotide polymorphism (SNP) within the OPRM1 gene, A118G, leading to an amino acid change (Asn40Asp) in the extracellular portion of the receptor, has been implicated in alcoholism as well as in drug addiction, pain sensitivity and stress response, and in animal and human studies relates to the alcohol-dependent phenotype as well as to the treatment response to the µ-opioid antagonist naltrexone.

CONCLUSION:

The effect size reported in naltrexone clinical studies is often small, which may be due to heterogeneity among patients. Pharmacogenetic approaches may help guide us in the search for the appropriate treatment optimal for one patient's need.

Place, publisher, year, edition, pages
Oxford University Press, 2013. Vol. 48, no 4, 402-408 p.
Keyword [en]
addiction, alcohol, naltrexone, pharmacogenetics, OPRM1-A118G
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:liu:diva-91026DOI: 10.1093/alcalc/agt030ISI: 000320856400006PubMedID: 23543091OAI: oai:DiVA.org:liu-91026DiVA: diva2:615724
Available from: 2013-04-11 Created: 2013-04-11 Last updated: 2017-12-06

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Authority records BETA

Thorsell, Annika

Search in DiVA

By author/editor
Thorsell, Annika
By organisation
Division of Cell BiologyFaculty of Health Sciences
In the same journal
Alcohol and Alcoholism
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 99 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • oxford
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf